The highest mutation rate was found in the high-risk group for the PTEN gene, a tumor immune tolerance mechanism, which is also known as MMAC1 and TEP1. Current research has found that PTEN gene abnormity can exist in many tumors such as glioblastoma, prostate cancer, endometrial cancer, etc. (47). This evidence concerns the gene TEP1 and prostate carcinoma.